The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More notably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammation associated with the disease. That said, physicians suggest that the largest unmet need for DES treatment is diagnosis. Annualized market revenues data for 9 key markets: US, France, Germany, Italy, Spain, UK, Japan, China, and India Annualized market revenues data from 2012 to 2022 and forecast from 2012 to 2022 Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by the 9 key markets. Pipeline candidates fall under major therapeutic classes

1. PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022
The Dry Eye Syndrome (DES) pipeline is strong, with 49 molecules in various phases of development. More
notably, the late-stage pipeline has three products with novel mechanisms of action to treat the inflammation
associated with the disease. That said, physicians suggest that the largest unmet need for DES treatment is
diagnosis.
Scope
Annualized market revenues data for 9 key markets: US, France, Germany, Italy, Spain, UK, Japan, China,
and India Annualized market revenues data from 2012 to 2022 and forecast from 2012 to 2022 Pipeline
analysis data providing a split across the different phases, mechanisms of action being developed and
emerging trends by the 9 key markets. Pipeline candidates fall under major therapeutic classes Analysis of key
recent licensing and partnership agreements in the DES Therapeutics market Insightful review of the key
industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative
analysis of its implications Key topics covered include strategic competitor assessment, market
characterization, unmet needs and implications.
Market Model Features
An interactive excel forecast model based on primary research interviews and surveys with KOLs and
high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates,
patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10
year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our
models support data presented in the reports and the complete methodology is outlined in the report and the
model.
*Model only available with site and global license purchases.
Key Findings
The global DES therapeutics market is forecast to reach $5.47 billion by 2022 due to the launch of novel
pipeline drugs and an aging population. The global push for increased physician and patient awareness will
increase diagnosis and treatment. By 2022, the DES market will be significantly more competitive, but the
current dearth of treatment options leave much room for the coming pipeline therapies.
Key Questions Answered in this Report
How will the patent expiry of Restasis affect the competitive landscape? What are the regional differences in
DES treatment? What are the drivers for growth in the DES market? Who is the frontrunner in the drug
pipeline for DES and what are its strengths and weaknesses? Will pipeline drugs find acceptance in the current
treatment paradigm? Where are companies investing R&D in 2013?
Key Benefits
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and
technologies and by identifying the companies with the most robust pipeline. Develop business strategies by
understanding the trends shaping and driving the global market. Drive revenues by understanding the key
trends, innovative products and technologies, market segments and companies likely to impact the market in
future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by
analyzing the performance of various competitors. Identify emerging players with potentially strong product
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

2. portfolios and create effective counter-strategies to gain a competitive advantage.
table Of Contents
1table Of Contents1
1.1list Of Tables5
1.2list Of Figures6
2executive Summary8
2.1significant Growth Is Expected In The Des Market From 2012-2022.8
2.2established Players Lack Strong Pipelines And Will Focus On Filling This Gap Through Acquisitions10
2.3with Only One Drug On The Market In The Us And Two In Japan, There Is A Significant Void To Fulfill
With Pipeline Products10
2.4the Real Opportunity For New Players To Market Their New Products And Expand The Patient Base
Relies On Improved Diagnosis.11
2.5pipeline Agents Offer Patients Expansion Into New Markets, Novel Mechanisms Of Action And
Longer-acting Delivery Systems.11
2.6what Do The Physicians Think?12
3introduction14
3.1catalyst14
3.2related Reports14
4disease Overview15
4.1etiology And Pathophysiology15
4.1.1etiology15
4.1.2pathophysiology16
4.1.3classification19
4.1.4prognosis19
4.1.5quality Of Life20
4.2symptoms20
5epidemiology21
5.1risk Factors And Comorbidities21
5.1.1risk Of Dry Eye Syndrome Increases 35% Each Decade After Age 4022
5.1.2women Are Twice As Likely To Have Dry Eye Syndrome As Men22
5.1.3use Of Certain Medications May Increase The Risk Of Developing Dry Eye Syndrome23
5.1.4diets Rich In Omega-3 Fatty Acids Help Prevent Dry Eye Syndrome24
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

3. 5.1.5certain Environmental Conditions Can Double The Risk Of Dry Eye Syndrome24
5.2global Trends24
5.2.1us24
5.2.25eu25
5.2.3asia25
5.3forecast Methodology26
5.3.1sources Used26
5.3.2forecast Assumptions And Methods27
5.3.3sources Not Used29
5.4epidemiology Forecast (2012–2022)30
5.4.1prevalent Cases Of Dry Eye Syndrome30
5.4.2age-specific Prevalent Cases31
5.4.3sex-specific Prevalent Cases34
5.4.4age-standardized Prevalence Of Dry Eye Syndrome35
5.5discussion36
5.5.1conclusions On Epidemiology Trends36
5.5.2limitations Of The Analysis39
5.5.3strengths Of The Analysis39
6disease Management39
6.1overview39
6.1.1diagnosis Overview39
6.1.2treatment Guidelines43
6.1.3treatment Overview47
6.2us50
6.2.1diagnosis50
6.2.2clinical Practice51
6.3france52
6.3.1diagnosis52
6.3.2clinical Practice53
6.4germany54
6.4.1diagnosis54
6.4.2clinical Practice54
6.5italy54
6.5.1diagnosis54
6.5.2clinical Practice54
6.6spain56
6.6.1diagnosis56
6.6.2clinical Practice56
6.7uk57
6.7.1diagnosis57
6.7.2clinical Practice57
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

4. 6.8japan57
6.8.1diagnosis57
6.8.2clinical Practice58
6.9china60
6.9.1diagnosis60
6.9.2clinical Practice60
6.10india61
6.10.1diagnosis61
6.10.2clinical Practice61
7competitive Assessment62
7.1overview62
7.2strategic Competitor Assessment62
7.3product Profiles – Major Brands63
7.3.1restasis (cyclosporine 0.05% Ophthalmic Emulsion)63
7.3.2diquas (diquafosol Tetrasodium)69
7.3.3mucosta (rebamipide 2% Ophthalmic Suspension)72
7.3.4additional Therapies75
8opportunity And Unmet Need78
8.1overview78
8.2diagnostic Tests Are Not Specific Enough To Identify Subgroups Of Patients80
8.3frequent Dosing And Side Effects Limit Compliance81
8.4lack Of Physician And Patient Awareness82
8.5trial Design May Be A Factor In So Few Drugs Being Approved83
8.6unmet Needs Gap Analysis84
8.7comprehensive Method For Measuring Dry Eye Signs And Severity Levels85
8.8increase Treatment Rates Among Milder Forms Of The Disease86
9pipeline Assessment86
9.1overview86
9.2clinical Trial Mapping87
9.2.1clinical Trials By Country87
9.2.2clinical Trials By Phase And Trial Status88
9.3promising Drugs In Clinical Development88
9.3.1lifitegrast90
9.3.2cf-10194
9.3.3cyclokat97
9.3.4egp-437101
9.3.5rx-10045105
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

5. 9.3.6mim-d3109
10current And Future Players112
10.1overview112
10.2trends In Corporate Strategy114
10.3company Profiles115
10.3.1allergan115
10.3.2alcon (a Wholly-owned Subsidiary Of Novartis Ag)117
10.3.3santen Pharmaceutical118
10.3.4shire/sarcode Bioscience123
10.3.5otsuka Holdings124
10.3.6can-fite Biopharma126
10.3.7eyegate Pharma128
11market Outlook129
11.1global Markets129
11.1.1forecast129
11.1.2drivers And Barriers – Global Issues131
11.2united States133
11.2.1forecast133
11.2.2key Events136
11.2.3drivers And Barriers137
11.3france140
11.3.1forecast140
11.3.2key Events141
11.3.3drivers And Barriers141
11.4germany144
11.4.1forecast144
11.4.2key Events146
11.4.3drivers And Barriers146
11.5italy148
11.5.1forecast148
11.5.2key Events150
11.5.3drivers And Barriers150
11.6spain152
11.6.1forecast152
11.6.2key Events154
11.6.3drivers And Barriers154
11.7united Kingdom154
11.7.1forecast154
11.7.2key Events157
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

6. 11.7.3drivers And Barriers157
11.8japan159
11.8.1forecast159
11.8.2key Events161
11.8.3drivers And Barriers161
11.9china163
11.9.1forecast163
11.9.2key Events165
11.9.3drivers And Barriers165
11.10india167
11.10.1forecast167
11.10.2key Events168
11.10.3drivers And Barriers168
12appendix169
12.1bibliography169
12.2abbreviations177
12.3methodology178
12.4forecasting Methodology178
12.4.1diagnosed Des Patients178
12.4.2percent Drug-treated Patients180
12.4.3drugs Included In Each Therapeutic Class180
12.4.4launch And Patent Expiry Dates180
12.4.5general Pricing Assumptions180
12.4.6individual Drug Assumptions182
12.4.7generic Erosion185
12.5physicians And Specialists Included In This Study186
12.6about The Authors187
12.6.1author187
12.6.2epidemiologist188
12.6.3reviewers189
12.6.4global Director Of Epidemiology And Clinical Trials Analysis190
12.6.5global Head Of Healthcare191
12.7about Globaldata192
12.8contact Us192
12.9disclaimer192
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022

7. which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Analysis to 2022